Apply by 31 August 2023

Swedish-French Accelerator 2.0

EIT Health Scandinavia and EIT Health France  in collaboration with Sweden’s innovation agency Vinnova invite Swedish companies working in precision health to apply to the second edition of the Swedish-French Accelerator program. Precision health includes precision medicine, personalised medicine and personalised health. The aim of this program is to provide expert support to the selected companies, enabling international collaborations, accelerating maturity, business expansion and access to the French market.

Program description:

The second edition of the Swedish French Accelerator program has a duration of 12 months and offers a unique combination of mentoring, onsite and online training sessions, that will help you validate your solution and fit to the French market within precision health. High level experts will assist you in addressing medical, regulatory, technical and business issues and prepare you to expand your innovative solution or business to France. Selected companies should expect at least 2 weeks of travel during the course of the program and approximately 1 day a week. It is therefore necessary to be able to dedicate the resources. No funding will go to the selected companies, but all expenses associated with participation will be reimbursed. After the program your company will have accelerated to the next maturity level(s).

The program runs from 20 October 2023 – 31 October 2024


The program includes acceleration within the following areas (non-exclusive):

  • Regulatory support
  • Access to clinical facilities
  • Collaboration opportunities
  • Incubatio
  • Talent growth/HR
  • Business training
  • Go-to-market strategy
  • Extension/Visibility in France
  • Travel and Accommodation
Who should apply:

Companies that aim to deliver precision health-based products and solutions to the healthcare system and wish to advance their solution to the next maturity levels or expand their businesses to France. The companies must have a maturity level between IML5-9. The companies should have ambitions for expansion either collaboratively or business wise and be able to see the benefits of doing so in France.

Selection process

Applications are screened for eligibility by the organisers and subsequently evaluated by a panel of independent expert reviewers. Overall selection criteria include your team and business potential, market need, current internationalisation efforts, and the impact that this program can have on your company.

Eligibility criteria:

  • The company must be registered/incorporated in Sweden.
  • The company must have between 2-49 full-time employee
  • The company must be incorporated on or no earlier than 01/01/2014.
  • The company must be working in the field of precision health which includes: Image analysis, Quality of life outcomes, Software components and Apps, Diagnostics, Digital biomarkers, Digital therapeutics, Drug screening platforms, Lab-on-a-chip, CRISPR technologies, Drug-target prediction and Regenerative medicine
  • The company must have a solution at an Innovation Maturity Level ranging from IML5-9.
  • The company must be a for-profit start-up/SME or have legal entity as defined by Horizon Europe.
  • Already raised funds (including public and/or private funds).

Once enrolled in the program each selected company will receive a 360° analysis and together with mentors a specific road map and action plan will be prepared for your company on how to benefit from or penetrate the French market.

Apply now

Application will be accepted between 10 June – 14 September 2023 (16:00 CET). All applications must be submitted in English on EIT Health’s platform by 14 September 2023.

Apply here

The program  runs from 20 October 2023 – 31 October 2024

EIT Health

We are a catalyst that brings together a network of Partners and investments, to make healthcare innovation happen. We fund projects and programmes across education, innovation and business creation, enabling the healthcare innovation needed for Europe’s economy to grow, sustainably. Our activities are strategically focused across flagship initiatives which address the underlying drivers of health. By utilising the expert capabilities in our network we have a proven track record in accelerating companies, and this excellence will be provided to companies enrolled in the Swedish-French Accelerator 2.0.


If you wish to discuss this opportunity in further details please contact: Scandinavian Team Per Horn, Entrepreneurship Lead French Team Robin Eggert-Griscelli, Collaboration Lead, EIT Health France.